The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.

Merck adds an overall survival benefit while Bristol sinks further.

Another KRAS G12D inhibitor hits the clinic, while Zai Lab hopes to banish the spectre of Rova-T. 

The Merck & Co drug's first successful phase 3 study might not be all it’s cracked up to be.